<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00197132</url>
  </required_header>
  <id_info>
    <org_study_id>49653/375</org_study_id>
    <nct_id>NCT00197132</nct_id>
  </id_info>
  <brief_title>Study In Patients With Insulin Resistance</brief_title>
  <official_title>A Single-centre, Randomised, Double-blind, Placebo Controlled, Two 12 Week Period, Cross-over Phase III Study to Investigate the Effect of Rosiglitazone 4mg bd on the Vasodilator Response to Hyperinsulinaemia in Obese Insulin Resistant Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Fluid management study in patients with insulin resistance.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">August 2003</completion_date>
  <primary_completion_date type="Actual">August 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forearm blood flow</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity, plasma volume, transcapillary escape rate, inhibition to vasodialtory response, changes in cardiac output, plasma catecholamine levels, changes in plasma hormone/markers of vascular permeability, safety and tolerability.</measure>
  </secondary_outcome>
  <enrollment type="Actual">18</enrollment>
  <condition>Insulin Resistance</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avandia</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 27-36 kg/m2 inclusive and at least two additional features of the metabolic
             syndrome or a first degree relative with a history of type 2 diabetes mellitus. BMI =
             Weight/height², (where weight is in kg, height in m).

          -  Male or female aged 30 to 65 years, inclusive, at screening.

          -  Female subjects must be post-menopausal (i.e. &gt;6 months without menstrual period),
             surgically sterile, or using effective contraceptive measures (oral contraceptives,
             Norplant Depo-Provera) or intra-uterine devices (IUD) (a diaphragm with spermicide or
             a condom with spermicide). Women of childbearing potential must use effective
             contraceptive measures for at least 1 month prior to visit 1, and should continue to
             use the same contraceptive method during the study and for 30 days after discontinuing
             study treatment.

          -  Willing and able to provide a signed and dated written informed consent.

        Exclusion Criteria:

          -  Subjects with type 2 diabetes mellitus defined as an HbA1c level &gt;6.5% or a fasting
             plasma glucose of &gt; 7.0 mmol/L. If fasting plasma glucose is between 6.1 and 7.0
             mmol/L then a 75 g oral glucose test will be performed to exclude diabetes mellitus.

          -  Subjects who have initiated lipid lowering therapy within the last 6 months and
             subjects who have increased the dose of these therapies within the last 3 months prior
             to study start.

          -  Subjects who are taking Non Steroidal Anti-inflammatory Drugs, fibrates,
             anticoagulants or cardiovascular medications (β-blockers, nitrates, calcium
             antagonists, ACE inhibitors, angiotensin II antagonists, alpha blockers, diuretics,
             centrally acting anti-hypertensives, directly acting antihypertensives e.g.,
             diazoxide, digoxin, anti-arrhythmics) and are unable to stop these medications for the
             duration of the study.

          -  Exposure to a thiazolidinedione (TZD) or other PPAR-γ agonist (e.g. rosiglitazone,
             troglitazone, pioglitazone, G1262570) within the last 4 months or participation in a
             clinical study involving a TZD or PPAR-γ agonist.

          -  Subjects who have required the use of any anti-diabetic medication at any time.

          -  Use of any investigational drug within 30 days preceding the first dose of medication
             at the start of the study.

          -  Subjects with a documented history of significant hypersensitivity (e.g. difficulty
             swallowing, difficulty breathing, tachycardia or skin reaction) to thiazolidinediones
             or PPAR-γ agonists.

          -  Systolic blood pressure &gt;160 mmHg or diastolic blood pressure &gt;100 mmHg or receiving
             antihypertensive therapy.

          -  Subjects with unstable or severe angina (requiring continual therapy) or congestive
             heart failure.

          -  Presence of clinically significant hepatic disease.

          -  Clinically significant anaemia.

          -  Subjects with creatinine clearance &lt;40 mL/min.

          -  Women who are lactating, pregnant or planning to become pregnant during the course of
             the study.

          -  Alcohol or drug abuse within the last 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525EZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>December 2, 2016</last_update_submitted>
  <last_update_submitted_qc>December 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin resistance vasodilatory response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>49653/375</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>49653/375</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>49653/375</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>49653/375</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>49653/375</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>49653/375</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>49653/375</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

